The BCL10 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the BCL10 gene has been disrupted to generate a loss-of-function model. This polyclonal format comprises a heterogeneous pool of edited cells, enabling robust and scalable gene-function studies without the confounding influence of single-cell clonal artifacts. The knockout model is designed for researchers aiming to dissect BCL10-dependent signaling pathways in an epithelial cancer background, offering a versatile tool for both mechanistic and translational investigations.
The parental A-549 cell line is a well-established human lung adenocarcinoma epithelial model, originally derived from a patient with non-small cell lung cancer (NSCLC). These cells harbor a KRAS mutation and are widely employed to study lung cancer biology, drug response, and signal transduction. Their epithelial phenotype makes them particularly suitable for exploring the role of BCL10 and NF-??B signaling in solid tumors, providing a platform distinct from classical immune-cell models.
BCL10 functions as an essential adaptor protein within the CARD11-BCL10-MALT1 (CBM) complex. Upon upstream stimulation, BCL10 is recruited by CARD11 (or the related CARD10) and engages MALT1, leading to the activation of the I??B kinase (IKK) complex. Activated IKK then phosphorylates I??B??, targeting it for degradation and liberating NF-??B to translocate to the nucleus. There, NF-??B drives transcription of multiple target genes, including the pro-inflammatory cytokines IL-6 and TNF-??, the anti-apoptotic factor Bcl-xL, and the ubiquitin ligases cIAP1/2. This cascade links signals from antigen receptors, C-type lectin receptors, and other upstream triggers mediated by protein kinase C isoforms (PKC??/PKC??) to broad transcriptional responses controlling cell survival, proliferation, and inflammation.
In A-549 cells, endogenous BCL10 may sustain baseline or stimulus-induced NF-??B activity, thereby supporting tumor cell fitness, resistance to apoptosis, and the secretion of inflammatory mediators. Disruption of BCL10 in this lung adenocarcinoma background permits the precise dissection of CBM-dependent NF-??B signaling in a non-immune epithelial environment. This model is especially valuable for investigating the contribution of BCL10 to solid tumor biology, where aberrant NF-??B activation is frequently associated with aggressive disease and therapeutic resistance.
The BCL10 Knockout A-549 Polyclonal Cells are suited for a broad array of experimental applications. Researchers can validate BCL10 disruption via Western blotting for BCL10 and phosphorylated p65, quantify transcript levels of NF-??B targets such as IL-6 and TNF-?? by RT-qPCR, and measure NF-??B transcriptional activity using luciferase reporter assays. The polyclonal pool also facilitates apoptosis assays (e.g., Annexin V staining), cell migration studies, and drug sensitivity screening targeting the CBM complex or downstream NF-??B pathway. For additional information, please contact Ascent Research.
